PMID- 28212539
OWN - NLM
STAT- MEDLINE
DCOM- 20180305
LR  - 20220330
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 16
DP  - 2017 Apr 18
TI  - Fluorescence in situ hybridization status of voided urine predicts invasive and 
      high-grade upper tract urothelial carcinoma.
PG  - 26106-26111
LID - 10.18632/oncotarget.15344 [doi]
AB  - Here, we assessed the diagnostic accuracy of fluorescence in situ hybridization 
      (FISH) for detecting aggressive upper tract urothelial carcinoma (UTUC). A total 
      of 210 UTUC patients from a single hospital in China were enrolled in this 
      retrospective study between 2012 and 2016. Patients were classified as 
      FISH-positive or -negative based on FISH analysis of voided urine, and the 
      clinicpathological characteristics of these two patient groups were compared. 
      Patients with positive FISH results had more advanced tumor stages and higher 
      tumor grades than those with negative results. The overall sensitivity of FISH 
      for detecting advanced UTUC was 62.4% (131/210). The sensitivity and positive 
      predictive values of positive FISH results were 76.5% and 59.5% for high-grade 
      UTUC and 71.7% and 58.0% for muscle-invasive UTUC. These data suggest that voided 
      urine FISH results accurately predict advanced UTUC and might help distinguish 
      patients with aggressive disease from those who might benefit from conservative 
      management.
FAU - Su, Xiaohong
AU  - Su X
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Hao, Han
AU  - Hao H
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Li, Xuesong
AU  - Li X
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - He, Zhisong
AU  - He Z
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Gong, Kan
AU  - Gong K
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Zhang, Cuijian
AU  - Zhang C
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Cai, Lin
AU  - Cai L
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Zhang, Qian
AU  - Zhang Q
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Yao, Lin
AU  - Yao L
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Ding, Yi
AU  - Ding Y
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Gong, Yanqing
AU  - Gong Y
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Fang, Dong
AU  - Fang D
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Zhang, Zheng
AU  - Zhang Z
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
FAU - Zhou, Liqun
AU  - Zhou L
AD  - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China.
AD  - Institute of Urology, Peking University, National Urological Cancer Center, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Cell-Free Nucleic Acids)
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Aged
MH  - *Cell-Free Nucleic Acids/urine
MH  - *DNA, Neoplasm/urine
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence/methods
MH  - Liquid Biopsy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Tumor Burden
MH  - Urologic Neoplasms/*diagnosis/*genetics/urine
PMC - PMC5432242
OTO - NOTNLM
OT  - conservative management
OT  - fluorescence in situ hybridization (FISH)
OT  - high grade
OT  - radical nephroureterectomy (RNU)
OT  - upper tract urothelial carcinoma (UTUC)
COIS- CONFLICTS OF INTEREST The authors of this article declare no conflicts of 
      interest.
EDAT- 2017/02/18 06:00
MHDA- 2018/03/06 06:00
PMCR- 2017/04/18
CRDT- 2017/02/18 06:00
PHST- 2016/09/23 00:00 [received]
PHST- 2017/01/24 00:00 [accepted]
PHST- 2017/02/18 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
PHST- 2017/02/18 06:00 [entrez]
PHST- 2017/04/18 00:00 [pmc-release]
AID - 15344 [pii]
AID - 10.18632/oncotarget.15344 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Apr 18;8(16):26106-26111. doi: 10.18632/oncotarget.15344.